X

LXRX

Lexicon Pharmaceuticals (LXRX) Q4 Loss Narrows to $0.04 Per Share Despite 79% Revenue Plunge to $5.5M

Lexicon narrows Q4 loss to $0.04 per share from $0.09 year-ago, but revenue plunges 79% to $5.5M amid commercialization challenges.

LXRX Reports Mixed Q4 Results: Loss Improves to $0.04 Per Share But Revenue Crashes 79% YoY

Lexicon narrows Q4 loss to $0.04 per share, down 55.6% YoY, but revenue plunges 79% to $5.5M amid biotechnology sector…

Lexicon Pharmaceuticals, inc (LXRX) Q2 2022 Earnings Call

Lexicon Pharmaceuticals, inc (NASDAQ: LXRX) Q2 2022 Earnings Conference

Lexicon Pharmaceuticals, inc (LXRX) Q1 2022 Earnings Call

Lexicon Pharmaceuticals, inc (NASDAQ: LXRX) Q1 2022 Earnings Conference

Lexicon Pharmaceuticals, inc (LXRX) Q3 2021 earnings conference call

Lexicon Pharmaceuticals, inc (NASDAQ: LXRX) Q3 2021 Earnings Conference

Lexicon Pharmaceuticals, inc (LXRX) 2Q21 Earnings Call

Lexicon Pharmaceuticals, inc (NASDAQ: LXRX) Q2 2021 Earnings Conference

Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2020 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Q1 2020 earnings call dated Apr. 27, 2020 Corporate Participants: Kimberly Lee — Head of Investor Relations and Corporate…